Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MESO | US
2.05
23.40%
Healthcare
Biotechnology
30/06/2024
04/10/2024
10.81
10.00
11.05
9.91
Mesoblast Limited engages in the development of regenerative medicine products in Australia the United States Singapore the United Kingdom and Switzerland. The company offers products in the areas of cardiovascular spine orthopedic disorder oncology hematology and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases including steroid refractory acute graft versus host disease acute respiratory distress syndrome and biologic refractory inflammatory bowel disease; and Remestemcel-L which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne Australia.
View LessPositive Momentum
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
118.4%1 month
98.2%3 months
83.6%6 months
78.7%-
454.55
1.81
0.25
0.18
-6.55
159.56
-
-56.08M
1.26B
1.26B
-
-1.25K
-
-41.20
-17.91
8.98
1.15
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
4.45
Range1M
5.05
Range3M
5.27
Rel. volume
3.03
Price X volume
4.75M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kura Oncology Inc | KURA | Biotechnology | 18.04 | 1.38B | -2.49% | n/a | 3.59% |
SPRY | SPRY | Biotechnology | 14.19 | 1.38B | -1.80% | n/a | 0.07% |
Tarsus Pharmaceuticals Inc | TARS | Biotechnology | 33.89 | 1.31B | 3.48% | n/a | 28.62% |
ELVN | ELVN | Biotechnology | 27.53 | 1.30B | 8.81% | n/a | 0.06% |
Avadel Pharmaceuticals plc | AVDL | Biotechnology | 13.09 | 1.26B | 0.23% | n/a | 53.59% |
Wave Life Sciences Ltd | WVE | Biotechnology | 8.41 | 1.24B | -4.76% | n/a | 656.70% |
Innoviva Inc | INVA | Biotechnology | 19.67 | 1.23B | 0.56% | 10.92 | 67.72% |
ANI Pharmaceuticals Inc | ANIP | Biotechnology | 57.83 | 1.22B | 0.57% | 49.40 | 68.04% |
Fluent Inc | COGT | Biotechnology | 11.11 | 1.22B | 3.64% | n/a | 4.87% |
PHATHOM PHARMACEUTICALS INC. | PHAT | Biotechnology | 17.25 | 1.20B | 2.92% | n/a | -216.56% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -6.55 | 0.76 | Cheaper |
Ent. to Revenue | 159.56 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 1.81 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 83.61 | 74.67 | Par |
Debt to Equity | 0.25 | -1.82 | Expensive |
Debt to Assets | 0.18 | 0.26 | Cheaper |
Market Cap | 1.26B | 3.73B | Emerging |